204 results about "Mouse Lung" patented technology

The invention discloses a pulmonary vascular endothelial barrier injury model and a construction method and application thereof, and relates to the technical field of biologication.The construction method of the pulmonary vascular endothelial barrier injury model comprises the following steps that a healthy mouse is adaptively fed for one week and then anesthetized with a medicine, oncostatin M recombinant protein is pretreated and then instilled into the lung of the mouse through an airway, and then the mouse is subjected to tumor cell apoptosis; obtaining a pulmonary vascular endothelial barrier injury model; the invention further discloses a pulmonary vascular endothelial barrier injury model, application of the model in preparation of a pulmonary vascular disease research model and application of the model in preparation of drugs for treating pulmonary vascular diseases. According to the pulmonary vascular endothelial barrier injury model as well as the construction method and the application thereof provided by the invention, the oncostatin M protein is combined with an oncostatin M receptor type II on an endothelial cell to activate a downstream signal channel, so that the endothelial barrier is damaged, a clear target spot is provided for the endothelial barrier injury, and a pulmonary injury mechanism can be deeply discussed.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

The invention belongs to the field of pharmacy, and relates to a medicine for treating pulmonary fibrosis, in particular to application of an anti-Gremlin1 antibody to preparation of a medicine for preventing and treating pulmonary fibrosis. The Gremlin1 antibody disclosed by the invention can be applied to prevention and treatment of pulmonary fibrosis, effectively improves bleomycin (BLM)-induced pulmonary fibrosis lesions of mice and improves the survival rate of the mice. Compared with a BLM group, the mouse inspiration capacity (IC) and the lung static compliance (CRS) treated by the Gremlin1 antibody are remarkably improved, the hydroxyproline content in lung tissue is remarkably reduced, and compared with the BLM group, the Ashcroft score, the collagen deposition area in Masson three-color dyeing and the Sirius red dyeing area of an antibody intervention group are remarkably reduced, and the proportion of activated endothelial cells and the proportion of transition-state epithelial cells are remarkably reduced. Therefore, the Gremlin1 antibody can be used for preparing the medicine for preventing and / or treating the pulmonary fibrosis.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention discloses a mouse lung organ and fibroblast co-culture method, which comprises the following steps of: performing in-vitro mouse lung organ culture on mouse lung tissue primary epithelial stem cell spheres (pneumospheroids) in a Transwell upper chamber, and after the lung organs in the Transwell upper chamber are differentiated, replacing with a lower chamber paved with mouse lung fibroblasts, therefore, a gas-liquid interface co-culture system of the mouse lung organ (upper chamber) and the fibroblast (lower chamber) is formed, and the hierarchical structure, morphological characteristics and regeneration function of the upper chamber organ and the phenotype, function and related signal path activation level of the lower chamber fibroblast can be dynamically researched.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention belongs to the field of biological agents, and particularly relates to application of polypeptide HRH and analogues thereof in preparation of drugs for treating pulmonary fibrosis. The amino acid sequence of the polypeptide HRH disclosed by the invention is NH2-His-Arg-His-Thr-Lys-Gln-Arg-His-Thr-Ala-Leu-His-CONH2. An in-vitro experiment proves that the polypeptide HRH can be used for effectively inhibiting pulmonary epithelial cell and fibroblast fibrosis induced by a transforming growth factor and silicosis fibrosis induced by silicon dioxide; in-vivo experiments further prove that the HRH can improve bleomycin-induced pulmonary fibrosis lesion of mice and improve weight loss and death rate of the mice, and meanwhile, the HRH has relatively high safety and no adverse toxic or side effect. The invention also provides an HRH polypeptide analogue which can more effectively inhibit the activation of fibroblasts. The polypeptide HRH prepared by the invention is low in dosage, safe and effective, and provides a potential new medicine for treating pulmonary fibrosis diseases.

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

The invention belongs to the technical field of application of plant exosomes, and discloses a plant-derived hybrid exosome and application of the plant-derived hybrid exosome in pulmonary fibrosis resistance. After screening a proper proportion, the obtained hybrid exosome has an obvious treatment effect on a mouse with pulmonary fibrosis induced by bleomycin, and the treatment effect is specifically shown as follows: (1) the hybrid exosome can obviously relieve lung inflammatory cell infiltration of the model mouse, protect a pulmonary alveolar structure and relieve the degree of pulmonary fibrosis; (2) the hybrid exosome can effectively reduce the expression levels of TNF-alpha, IL-1beta and IL-6, and can effectively slow down the pulmonary fibrosis process; the lung tissue inflammation is inhibited; and (3) the hybridized exosome inhibits the generation of ECM (extracellular matrix) and inhibits epithelial mesenchymal transition, so that the anti-fibrosis effect is achieved. The plant source hybrid exosome prepared by the invention is wide in plant source, simple in exosome preparation process and low in cost, and provides new possibility for treating pulmonary fibrosis.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The invention discloses an inflammatory pulmonary epithelium injury treatment evaluation method based on alveolar organs, and relates to the technical field of medical biology. The invention mainly aims at alveolar epithelium injury and repair in inflammatory lung injury, and establishes an organ-like model for simulating alveolar epithelium injury. By using the model, the efficacy of related drugs on alveolar epithelium injury repair can be detected in a targeted manner, and an efficient drug screening and evaluation platform and method are provided for pulmonary epithelium repair in inflammatory lung injury. According to the technical scheme, the method comprises the steps that mouse alveolar epithelial stem cells are separated through magnetic bead sorting, an alveolar organoid inflammatory lung injury model is established through LPS exposure, alveolar organoid is treated through drugs, the organoid generation number, the organoid formation rate, the epithelial cell proliferation rate and the AT2-AT1 differentiation efficiency are detected, and the drug treatment effect is evaluated.

The invention belongs to the technical field of gene engineering, and particularly relates to a pleural mesothelioma animal model construction method and application capable of simulating immunotherapy response, and the method comprises the following steps: culturing human or mouse lung cells into a first organ, carrying out TrypLE resuspension digestion into single cells, carrying out genetic modification, and culturing into a second organ; the genetic modification is one of the following modes: I, knocking out Trp53, Pten, Cdkn2a and Cdkn2b genes, and overexpressing a Sox2 mutant gene and a Myc gene; and II, knocking out the Trp53 gene, the Pten gene, the Cdkn2a gene, the Cdkn2b gene and the Bap1 gene, and carrying out overexpression on the Sox2 mutant gene and the Myc gene. Resuspending and digesting the second organ to prepare a cell suspension; and injecting the mixture between the dirty layer pleura of the mouse, and culturing for 90-120 days to construct the pleural mesothelioma mouse model. Compared with a transplanted tumor animal model, the method has the advantages that the animal model keeps a natural microenvironment for tumor generation and development in an animal body, and the accuracy is higher in the aspect of simulating real clinical patient conditions.

The invention relates to the technical field of biological medicines, and provides application of Miltefosine in preparation of a medicine for treating pulmonary fibrosis. According to the invention, the treatment effect of Miltefosine is systematically evaluated by constructing a plurality of mouse pulmonary fibrosis models. Research results show that Miltefosine can significantly reduce the degree of pulmonary fibrosis, and has no obvious toxicity to liver and kidney functions and important organs. Besides, in-vitro experiments prove that Miltefosine can play an anti-fibrosis role by inhibiting activation, proliferation and migration of fibroblasts induced by TGF-beta1 and promoting apoptosis of the fibroblasts. The researches provide important theoretical and experimental basis for Miltefosine'new use of old medicine 'in treatment of pulmonary fibrosis.

The present invention discloses the preparation of patchouli flavonoid nanoliposomes and their application in inhalation treatment of acute lung injury, and relates to the field of medical technology. The patchouli flavonoid nanoliposomes provided by the present invention prepare patchouli flavonoids into a liposome dosage form, which has good stability and biocompatibility. The drug is administered to mice with acute lung injury, so that patchouli flavonoids can act on the mouse lungs in a targeted manner, reduce the expression of inflammatory factors such as IL-6, IL-1β and TNF-α in the mouse lungs to relieve inflammation, improve pulmonary edema, and reduce lung tissue damage, while increasing the levels of tight junction factors such as ZO-1, VE-Cadherin, E-Cadherin and Claudin5 to repair lung barrier damage. The present invention is expected to provide an effective strategy for the treatment of acute lung injury.

The invention discloses application of ceftriaxone sodium in preparation of a medicine for preventing and / or treating pulmonary nodules, and belongs to the technical field of tumor prevention and treatment, ceftriaxone sodium is converted into inhalable aerosol particles through an aerosol inhalation device, targeted delivery of the medicine to the lung can be achieved, systemic adverse reactions caused by systemic administration are remarkably reduced, and the curative effect of the medicine is improved. Therefore, the medicine has a treatment effect on pulmonary nodules. Experimental results in the early stage prove that ceftriaxone sodium with different concentrations is subjected to aerosol inhalation to intervene in a mouse pulmonary nodule model induced by uratan, and the ceftriaxone sodium has a good prevention and treatment effect. The research can provide new experimental basis and reference for development of lung nodule related prevention and treatment medicines, provides new technical ideas for prevention and treatment of other diseases, and has important academic value and potential of further development and research.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

This invention belongs to the field of biomedical technology and discloses the application of KDELR3 inhibitors in the preparation of drugs for the prevention and / or treatment of individual fibrotic diseases. In a wild-type mouse model of pulmonary fibrosis, compared with the control group receiving intratracheal injection of Scr siRNA, intratracheal injection of KDELR3 siRNA significantly reduced the degree of fibrosis in the mouse lung tissue. KDELR3 inhibition significantly reduced collagen deposition and improved lung tissue structural damage. Further mechanistic studies showed that KDELR3 inhibitors can inhibit the differentiation of fibroblasts into myofibroblasts, thereby reducing the production of fibrosis-related extracellular matrix. These results indicate that KDELR3 is a key molecule regulating the occurrence and development of fibrosis, and drugs that can inhibit KDELR3 expression or activity can be used to prevent and treat various fibrotic diseases, including pulmonary fibrosis, laying the foundation for the development of novel drugs that are effective and safe in treating fibrotic diseases.

The invention belongs to the technical field of biomedical detection, and particularly relates to a standardized lung tissue microthrombus digital quantitative analysis method. Comprising the following steps: S1, embedding a left lung lobe of a complete mouse by using paraffin to obtain a wax block, slicing the wax block, and selecting a slice which can completely display each tissue structure of the lung at a lung door for dyeing and analysis; s2, paraffin sections are immersed, rinsed and subjected to antigen repair; blocking endogenous peroxidase of the paraffin section, and closing a non-specific binding site of the paraffin section to obtain a paraffin section tissue; s3, preparing a primary antibody working solution to carry out antigen-primary antibody reaction; preparing an HRP secondary antibody working solution and carrying out primary antibody-secondary antibody reaction; s4, carrying out DAB color development by using a DAB color development solution, re-dyeing the cell nucleus by using hematoxylin, and carrying out immersion, dip dyeing and dehydration treatment to obtain a transparent sealing sheet; s5, using a full-automatic slide scanner to obtain a lung tissue panoramic digital scanning picture; and S6, performing batch analysis on the mouse lung tissue microthrombus by using an HALO pathological image analysis platform.

The invention discloses a non-exposed airway instillation administration method for mouse lung specific administration, which comprises the following steps of: 1, preparing different types of drugs to be administered, namely a hydrophilic drug, a hydrophobic drug and a cellular drug; 2, the mouse is placed in a matched anesthesia device, and anesthesia treatment is conducted on the mouse; then the anesthetized mouse is placed on a matched hanging device, and the body of the mouse naturally droops; 3, the tongue of the mouse is pulled out through bent tweezers until the mouse feels resistance, and the action can open the epiglottis and expose the airway; 4, applying a medicine to the root of the tongue by using a pipettor, and covering the nasal cavity of the mouse by using the finger wearing the glove; meanwhile, the tongue of the mouse is maintained to extend outwards and the nasal cavity is covered for 10 breaths, and administration is completed; compared with the common lung tissue drug delivery technology at present, the non-exposed airway instillation drug delivery method provided by the invention has remarkable comprehensive advantages, and low-cost, non-invasive and multi-time mouse lung tissue specific drug delivery of cell / non-cell drugs can be realized.

The invention belongs to the technical field of animal models, and particularly relates to a method for visually and noninvasively constructing a chronic pulmonary fibrosis model and application. According to the improved novel visual non-invasive uniform administration mouse pulmonary fibrosis modeling method disclosed by the invention, an irreversible pulmonary fibrosis mouse model with wide injury can be successfully established, and the pulmonary fibrosis degree of the mouse model is gradually aggravated along with the prolonging of modeling time within one month; the disease shows a chronic inflammation and progressive pulmonary fibrosis; the obtained pulmonary fibrosis model is high in success rate, uniform in pathological degree, short in experimental period, low in cost and easy and convenient to operate, the mouse pulmonary fibrosis model constructed through the method is high in success rate and low in mouse death rate, and the pathological result of the constructed mouse pulmonary fibrosis model is closer to clinical pathological characteristics.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The present disclosure provides use of a hematopoietic cell kinase (HCK) inhibitor in preparation of a drug for treating pulmonary fibrosis, and relates to the technical field of biomedicine. In the present disclosure, idiopathic pulmonary fibrosis (IPF) model mice are used as a subject to allow research. Administration of an HCK inhibitor RK-20449 to IPF mice can effectively alleviate the progression of pulmonary fibrosis. A weight and a survival rate of the IPF mice have improved to a certain extent, and their lung function has improved significantly. The transcription levels of inflammatory factors Il-1β, Il-6, and Tnf-α in a lung tissue of the IPF mice have decreased, while the concentrations of inflammatory factors IL-1β and IL-6 in the alveolar lavage fluid have also decreased. The transcription levels of fibrosis factors Col-I and Fn-1 are decreased, the collagen-specific amino acid hydroxyproline is decreased, and the degree of lesions is alleviated.